BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//GeneOnline Conference - ECPv4.4.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GeneOnline Conference
X-ORIGINAL-URL:https://conference.geneonline.news
X-WR-CALDESC:Events for GeneOnline Conference
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230228
DTEND;VALUE=DATE:20230428
DTSTAMP:20230318T202714
CREATED:20230110T075853Z
LAST-MODIFIED:20230110T080636Z
UID:8105-1677542400-1682726399@conference.geneonline.news
SUMMARY:BCIC 2023 Biomedical Pitch Competition
DESCRIPTION:You are invited to the BCIC 2023 Biomedical Pitch Competition\, connecting high-quality biomedical start-ups with investors and other business accelerator resources. Please submit your Application by February 28th\, 2023. Biomedical start-ups at any stage are welcome.\n\nWhy should Your Team Join?\n-Top three winning startup teams will get both cash award and other credits;\n-Potential direct equity investment from 100+ Angel/VC funds\n-Mentorship & Partnership opportunities from venture capitalists\, serial entrepreneurs\, corporate executives\, and attorneys;\n-Max Media exposure through cohosts' network; \n-Discounted services on incubator\, startup Bootcamp\, and financials;\n\nTimeline:\nAccepting Applications: Dec 2022 - Feb 2023\nQualified individuals or organizations can register by scanning the QR Code \n\n\nOr link http://bcicglobal.mikecrm.com/w9wB3Ht \n \n\n \n\n
URL:https://conference.geneonline.news/event/bcic-2023-biomedical-pitch-competition/
ATTACH;FMTTYPE=image/png:https://conference.geneonline.news/wp-content/uploads/2023/01/螢幕快照-2023-01-10-16.03.10.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230328
DTEND;VALUE=DATE:20230329
DTSTAMP:20230318T202714
CREATED:20230313T034008Z
LAST-MODIFIED:20230313T034142Z
UID:8139-1679961600-1680134399@conference.geneonline.news
SUMMARY:Reuters Events: Pharma USA 2023
DESCRIPTION:Patient-first. Collaborative. Data and insights driven. Digitally underpinned.\nThese are the qualities of a healthcare system that actively serves its purpose – yet instead\, the US is hindered by mounting financial toxicity\, unprecedented politicization of science and eroding public trust.\n\nTo capitalize on three years of extraordinary momentum and lead healthcare’s reform\, pharma must embody the traits that healthcare needs to thrive and restructure in pursuit of change.\n\nSeize the moment at Reuters Events: Pharma USA 2023 to lead pharma’s internal revolution and drive this critical systemic transformation. Join North America’s visionary pharma changemakers\, leading solution providers\, patient experts and industry heavyweights to catapult commercial excellence\, ingrain patient-first strategies into the heart of pharma’s fabric and heed the long-awaited rebirth of America’s healthcare system.\n\n\n\n 
URL:https://conference.geneonline.news/event/reuters-events-pharma-usa-2023/
LOCATION:美國
ATTACH;FMTTYPE=image/jpeg:https://conference.geneonline.news/wp-content/uploads/2023/03/1678678779305.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230331
DTEND;VALUE=DATE:20230401
DTSTAMP:20230318T202714
CREATED:20221215T015848Z
LAST-MODIFIED:20221215T015848Z
UID:8065-1680220800-1680393599@conference.geneonline.news
SUMMARY:2023 亞太胞外體學會大會
DESCRIPTION:台灣首次辦理亞太胞外體學會大會，活動將在2023/3/31-4/1於南港生醫園區，聚集來自日本、韓國、澳洲、紐西蘭、台灣的產學研菁英，共同探討從基礎科學、臨床應用到新興趨勢等胞外體重要議題。\n\n活動內容除重要技術發表，同時有海報及研究主題發表徵件，難得盛會不容錯過，快火速投稿、手刀報名。\n \n\n\n立即報名：https://www.accupass.com/event/2212011014077780859640
URL:https://conference.geneonline.news/event/2023-tsev/
ATTACH;FMTTYPE=image/png:https://conference.geneonline.news/wp-content/uploads/2022/12/螢幕快照-2022-12-15-09.55.13.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230403
DTEND;VALUE=DATE:20230404
DTSTAMP:20230318T202714
CREATED:20230109T095454Z
LAST-MODIFIED:20230109T095852Z
UID:8086-1680480000-1680652799@conference.geneonline.news
SUMMARY:CGT Asia 2023第三屆亞洲細胞與基因治療創新峰會
DESCRIPTION:細胞基因治療（CGT）已成為新一代突破性的精準治療手段，相關臨床轉化和商業化正在加速進行。據弗若斯特沙利文數據，預計到2025年，全球CGT市場規模將達到約305.4億美元，2020-2025年CAGR為71%。中國CGT領域的整體熱度也在不斷提高，2022年中國CGT治療市場規模預計同比增長1025.21%，隨後仍將保持100%以上的高增長趨勢，中國CGT市場規模2025年有望達到 178.9 億人民幣，2020-2025年CAGR 高達276%。\n2022年5月10日，中國官方單位發布了《“十四五”生物經濟發展規劃》。該規劃明確指出要重點發展基因治療、幹細胞治療、免疫細胞治療等新技術，強化產學研用協同聯動，加快相關技術產品轉化和臨床應用。\n有利的法規政策、資金的認可和支持、大量未被滿足的臨床需求、CAR-T資質醫院的落地等驅動因素，都將進一步促進中國CGT市場發展。然而行業高速發展也意味著在技術、生產和商業化等各方面面臨更大挑戰，細胞基因治療新藥研發、產品商業化道路、罕見病治療藥物開發、相關醫保方案等眾多行業人士熱切關注的問題亟待解答。\n在此背景下，由Taas Labs談思生物主辦的CGT Asia 2023第三屆亞洲細胞與基因治療創新峰會將於2023年4月3日-4日在上海召開。同時，本次大會特設“CGT Awards CGT行業之星”2023年度亞太區細胞與基因治療行業之星獎項評選，面向全球，所有企業或團隊均可免費報名參與，設有10+個“CGT行業之星”獎項，採用線上投票和專家評審方式，旨在為細胞與基因治療科研轉化方向提供強有力支持，促進提升行業研發實力，提升品牌影響力，促進全行業研發進展。峰會持續2天，設有2個論壇&專業技術展，屆時將有50+位各國行業大咖分享經驗見解與應用案例，60+個精品展位展示最新技術與解決方案，200+家全球細胞治療與基因治療相關企業共同參與，1500+專業人士蒞臨，共話產業前景與合作機會，內容聚焦細胞治療產品佈局及商業化、幹細胞治療新藥研發進展、智能科技支撐商業化通路、細胞治療上市背景下的醫保方案探討、基因治療最新熱點與創新研發佈局、藥物開發優化與遞送技術、加強研發轉化從實驗室到臨床、罕見病基因治療藥物開發等核心話題，致力於促進細胞基因治療科研技術創新與產業融合發展，著力於打造一場細胞與基因治療領域的饕餮盛宴。\n\n立即前往：https://genetherapy-asia.taaslabs.com/index.php/cn\n
URL:https://conference.geneonline.news/event/cgt-asia-2023cgt/
ATTACH;FMTTYPE=image/png:https://conference.geneonline.news/wp-content/uploads/2023/01/螢幕快照-2023-01-09-17.48.36.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230424
DTEND;VALUE=DATE:20230425
DTSTAMP:20230318T202714
CREATED:20230110T071129Z
LAST-MODIFIED:20230311T191748Z
UID:8091-1682294400-1682467199@conference.geneonline.news
SUMMARY:Cell & Gene Therapy Summit 2023
DESCRIPTION:Under the stewardship of The Economist editors\, our inaugural event on cell and gene therapies convenes industry stakeholders to accelerate access to transformative products.\n\nCell and gene therapies are redefining the treatment of many diseases\, giving hope to patients who previously had no therapeutic options. These treatments can be transformative in the battle against cancer\, genetic disorders and rare diseases. In the UK\, NICE expects to review 30 new cell and gene therapy products by 2023\, with the FDA in the US predicting between 15 and 20 new products will be on the market by 2025. Attendees will learn how healthcare systems and policies need to evolve before these therapies can become mainstream.\nThrough a series of interactive sessions\, industry stakeholders will debate the challenges of bringing these therapies to market—including manufacturing\, real-world data collection and their commercial sustainability. Our conference programme examines the potential for a healthcare paradigm shift\, as public opinion and patient experience evolve. We will also assess the innovations needed in pricing policies and payments to combat “big sticker” price tags—some products are $2.48 million per dose—and how they limit accessibility.\nApril 24th – 25th 2023 • Brussels\, Belgium\nEnabling market access\, policy\, and delivery\nMore about the event\n[video width="1496" height="600" mp4="https://conference.geneonline.news/wp-content/uploads/2023/01/Cell-and-Gene-Therapy-Summit.mp4"][/video]\n\n 
URL:https://conference.geneonline.news/event/cell-gene-therapy-summit-2023/
CATEGORIES:The Economist
ATTACH;FMTTYPE=image/png:https://conference.geneonline.news/wp-content/uploads/2023/01/螢幕快照-2023-01-10-15.36.03.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231116
DTEND;VALUE=DATE:20231117
DTSTAMP:20230318T202714
CREATED:20230103T030843Z
LAST-MODIFIED:20230103T031417Z
UID:8077-1700092800-1700265599@conference.geneonline.news
SUMMARY:3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
DESCRIPTION:The main motto of our Nutrition conference is to give a fruitful experience to all its participants across the globe.  It’s going to be one platform where you share your research work and thoughts and the same time gain knowledge from various other international speakers in all the interdisciplinary fields of nutrition and healthcare. The Nutrition conference encompasses keynote sessions\, oral presentations\, E-posters\, video presentations\, panel discussions\, networking sessions\, workshops.\n \nRegister Now\n
URL:https://conference.geneonline.news/event/3rd-international-conference-on-nutrition-and-healthcare/
ATTACH;FMTTYPE=image/png:https://conference.geneonline.news/wp-content/uploads/2023/01/螢幕快照-2023-01-03-11.13.23.png
END:VEVENT
END:VCALENDAR